Pomerantz Law Firm Launches Class Action Against Nektar Therapeutics Over Securities Violations

Class Action Lawsuit Filed Against Nektar Therapeutics

On April 30, 2026, Pomerantz LLP announced that a class action lawsuit has been launched against Nektar Therapeutics, a biopharmaceutical entity listed on the NASDAQ under the symbol NKTR, as well as select company officers. The lawsuit was filed in the Northern District of California and is officially registered under the docket number 26-cv-01951. This action is being pursued on behalf of all individuals and entities other than the defendants that acquired Nektar securities between February 26, 2025, and December 15, 2025, a period during which significant misrepresentations regarding the company’s business operations were allegedly made.

The suit aims to recover damages attributed to these violations of federal securities laws and is seeking remedies under Sections 10(b) and 20(a) of the Securities Exchange Act along with Rule 10b-5, which is associated with fraudulent activities in the sale of securities.

Key Details of the Lawsuit

The law firm emphasized that any investor who purchased or acquired Nektar securities during the aforementioned class period has until May 5, 2026, to request that the court designate them as Lead Plaintiff in the case. Interested parties can obtain a copy of the formal Complaint via the Pomerantz Law Firm’s website, while inquiries can be made through the contact information provided in the press release.

Nektar Therapeutics is recognized for its commitment to developing therapies that aim to regulate the immune system to combat various autoimmune disorders. Its leading candidate, rezpegaldesleukin, also referred to as REZPEG or NKTR-358, is a groundbreaking T cell stimulator expected to address conditions such as alopecia areata.

In March 2024, Nektar initiated a Phase 2b clinical trial named REZOLVE-AA, focusing on 94 patients suffering from severe to very severe alopecia areata, who had not previously undergone treatment with Janus kinase inhibitors or other biologics. Notably, the trial's parameters included strict enrollment criteria necessitating a proper diagnosis as measured by the Severity of Alopecia Tool upon initial screening, along with the exclusion of patients with unstable conditions over the past six months.

In February 2025, Nektar reported that it met its targeted enrollment for the REZOLVE-AA trial. Throughout this period, the defendants maintained that the enrollment processes adhered to established guidelines and that their expertise in drug development would significantly enhance the progress of their product candidates.

The lawsuit claims that during the class period, the defendants issued materially misleading statements regarding Nektar’s business operations and compliance protocols. Specifically, they are accused of failing to disclose critical information, including that enrollment for the trial deviated from prescribed standards and that such deviations could adversely affect the trial’s outcomes and the overall credibility of the results announced.

The truth surrounding the trial's issues surfaced on December 16, 2025, when Nektar issued a press release revealing that the results of the 36-week induction treatment phase of the REZOLVE-AA trial did not yield statistical significance, attributing the failure to the inclusion of ineligible participants. Following this announcement, Nektar's stock price experienced a significant dip, dropping $4.14 per share or approximately 7.77%, concluding the day at $49.16 per share.

About Pomerantz LLP

Pomerantz LLP, with its main offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has established a reputation as a leader in corporate, securities, and antitrust class action litigation. Founded by Abraham L. Pomerantz, who is often referred to as the pioneer of class action law, the firm has been a relentless advocate for victims of securities fraud and corporate misconduct for over 85 years. Pomerantz has notably recovered billions of dollars in damages for its clients, underscoring its continued commitment to pursuing justice in the complex world of corporate accountability.

For further information or to participate in the class action, interested investors should reach out to Pomerantz LLP’s Danielle Peyton at the contact details provided above. This communication is attorney advertising; past results do not guarantee similar outcomes.